The Experience of a Single Tertiary Center Regarding Benign and Malignant Tumors in Acromegalic Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Statistical Analysis
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lavrentaki, A.; Paluzzi, A.; Wass, J.A.H.; Karavitaki, N. Epidemiology of acromegaly: Review of population studies. Pituitary 2017, 20, 4–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, K.; Guo, X.; Yu, S.; Gao, L.; Wang, Z.; Zhu, H.; Xing, B.; Zhang, S.; Dong, D. Patient-Identified Problems and Influences Associated with Diagnostic Delay of Acromegaly: A Nationwide Cross-Sectional Study. Front. Endocrinol. 2021, 12, 704496. [Google Scholar] [CrossRef]
- Găloiu, S.; Poiană, C. Current therapies and mortality in acromegaly. J. Med. Life 2015, 8, 411–415. [Google Scholar] [PubMed]
- Ruchala, M.; Wolinski, K. Health related Complications of Acromegaly-Risk of Malignant Neoplasms. Front. Endocrinol. 2019, 10, 268. [Google Scholar] [CrossRef] [PubMed]
- Dal, J.; Leisner, M.Z.; Hermansen, K.; Farkas, D.K.; Bengtsen, M.; Kistorp, C.; Nielsen, E.H.; Andersen, M.; Feldt-Rasmussen, U.; Dekkers, O.M.; et al. Cancer Incidence in Patients with Acromegaly: A Cohort Study and Meta-Analysis of the Literature. J. Clin. Endocrinol. Metab. 2018, 103, 2182–2188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cooper, G.M. Cancer in The Cell: A Molecular Approach, 2nd ed.; Sinauer Associates Inc.: Washington, DC, USA; Sunderland, MA, USA, 2000; Chapter 15; ISBN 0-87893-106-6. Available online: https://www.ncbi.nlm.nih.gov/books/NBK9839/ (accessed on 3 January 2023).
- Minamoto, T.; Mai, M.; Ronai, Z.E. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 1999, 20, 519–527. [Google Scholar] [CrossRef] [PubMed]
- Konstantinos, I.A.; Nikolaos, S.; Christos, S.M.; Maria, D. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism 2019, 92, 121–135. [Google Scholar] [CrossRef]
- Gadelha, M.R.; Kasuki, L.; Lim, D.S.T.; Fleseriu, M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocr. Rev. 2019, 40, 268–332. [Google Scholar] [CrossRef] [Green Version]
- Dworakowska, D.; Grossman, A.B. Colonic Cancer and Acromegaly. Front. Endocrinol. 2019, 10, 390. [Google Scholar] [CrossRef]
- Poloz, Y.; Stambolic, V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015, 6, e2037. [Google Scholar] [CrossRef] [Green Version]
- Esposito, D.; Ragnarsson, O.; Johannsson, G.; Olsson, D.S. Incidence of Benign and Malignant Tumors in Patients with Acromegaly Is Increased: A Nationwide Population-based Study. J. Clin. Endocrinol. Metab. 2021, 106, 3487–3496. [Google Scholar] [CrossRef] [PubMed]
- Matyjaszek-Matuszek, B.; Obel, E.; Lewicki, M.; Kowalczyk-Bołtuć, J.; Smoleń, A. Prevalence of neoplasms in patients with acromegaly—The need for a national registry. Ann. Agric. Environ. Med. 2018, 25, 559–561. [Google Scholar] [CrossRef]
- Protocol Terapeutic Corespunzător Poziţiei. Available online: https://cnas.ro/wp-content/uploads/2023/03/D-J.pdf (accessed on 2 June 2023).
- Tessler, F.N.; Middleton, W.D.; Grant, E.G.; Hoang, J.K.; Berland, L.L.; Teefey, S.A.; Cronan, J.J.; Beland, M.D.; Desser, T.S.; Frates, M.C.; et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J. Am. Coll. Radiol. 2017, 14, 587–595. [Google Scholar] [CrossRef] [Green Version]
- Cook, D.M. Growth hormone and estrogen: A clinician’s approach. J. Pediatr. Endocrinol. Metab. 2004, 17 (Suppl. S4), 1273–1276. [Google Scholar] [PubMed]
- Hobbs, C.J.; Plymate, S.R.; Rosen, C.J.; Adler, R.A. Testosterone administration increases insulin-like growth factor-I levels in normal men. J. Clin. Endocrinol. Metab. 1993, 77, 776–779. [Google Scholar] [CrossRef] [PubMed]
- Chhabra, Y.; Waters, M.J.; Brooks, A.J. Role of the growth hormone-IGF-1 axis in cancer. Expert Rev. Endocrinol. Metab. 2011, 6, 71–84. [Google Scholar] [CrossRef] [Green Version]
- Burton, T.; Le Nestour, E.; Neary, M.; Ludlam, W.H. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary 2016, 19, 262–267. [Google Scholar] [CrossRef] [Green Version]
- Dal, J.; Skov, B.G.; Andersen, M.; Feldt-Rasmussen, U.; Feltoft, C.L.; Karmisholt, J.; Nielsen, E.H.; Dekkers, O.M.; Jørgensen, J.O.L. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature. Clin. Endocrinol. 2021, 94, 625–635. [Google Scholar] [CrossRef]
- Terzolo, M.; Reimondo, G.; Berchialla, P.; Ferrante, E.; Malchiodi, E.; De Marinis, L.; Pivonello, R.; Grottoli, S.; Losa, M.; Cannavo, S.; et al. Acromegaly is associated with increased cancer risk: A survey in Italy. Endocr.-Relat. Cancer 2017, 24, 495–504. [Google Scholar] [CrossRef] [Green Version]
- Iliana, C.L.; Lorraine, L.L. Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications. Endocr. Rev. 2020, 41, 33–52. [Google Scholar] [CrossRef]
- Duan, W.; Shen, X.; Lei, J.; Xu, Q.; Yu, Y.; Li, R.; Wu, E.; Ma, Q. Hyperglycemia, a neglected factor during cancer progression. BioMed Res. Int. 2014, 2014, 461917. [Google Scholar] [CrossRef] [Green Version]
- Kasprzak, A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. Int. J. Mol. Sci. 2021, 22, 6434. [Google Scholar] [CrossRef]
- Brahmkhatri, V.P.; Prasanna, C.; Atreya, H.S. Insulin-like growth factor system in cancer: Novel targeted therapies. BioMed Res. Int. 2015, 2015, 538019. [Google Scholar] [CrossRef] [Green Version]
- Lauby-Secretan, B.; Scoccianti, C.; Loomis, D.; Grosse, Y.; Bianchini, F.; Straif, K. International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer—Viewpoint of the IARC Working Group. N. Engl. J. Med. 2016, 375, 794–798. [Google Scholar] [CrossRef] [Green Version]
- Ding, N.; Maiuri, A.R.; O’Hagan, H.M. The emerging role of epigenetic modifiers in repair of DNA damage associated with chronic inflammatory diseases. Mutat. Res. Rev. Mutat. Res. 2019, 780, 69–81. [Google Scholar] [CrossRef] [PubMed]
- Cheng, S.; Gomez, K.; Serri, O.; Chik, C.; Ezzat, S. The role of diabetes in acromegaly associated neoplasia. PLoS ONE 2015, 10, e0127276. [Google Scholar] [CrossRef]
- Espinosa-de-los-Monteros, A.L.; González, B.; Vargas, G.; Sosa, E.; Mercado, M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 2011, 14, 231–235. [Google Scholar] [CrossRef] [PubMed]
- Portocarrero-Ortiz, L.A.; Vergara-Lopez, A.; Vidrio-Velazquez, M.; Uribe-Diaz, A.M.; García-Dominguez, A.; Reza-Albarrán, A.A.; Cuevas-Ramos, D.; Melgar, V.; Talavera, J.; Rivera-Hernandez, A.D.J.; et al. The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes. J. Clin. Endocrinol. Metab. 2016, 101, 3997–4004. [Google Scholar] [CrossRef] [Green Version]
- Slopien, R.; Wender-Ozegowska, E.; Rogowicz-Frontczak, A.; Meczekalski, B.; Zozulinska-Ziolkiewicz, D.; Jaremek, J.D.; Cano, A.; Chedraui, P.; Goulis, D.G.; Lopes, P.; et al. Menopause and diabetes: EMAS clinical guide. Maturitas 2018, 117, 6–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- International Agency for Research on Cancer. Available online: https://gco.iarc.fr/today/data/factsheets/populations/642-romania-fact-sheets.pdf (accessed on 3 March 2023).
- Teodoriu, L.; Ungureanu, M.C.; Leustean, L.; Preda, C.; Ciobanu, D.; Grierosu, I.; Matei, M.; Iacob, R.; Stefanescu, C. Updated Incidence of Thyroid Cancer in the North East Region of Romania after 35 Years of Chernobyl Fallout. Is There a Link between? Diagnostics 2021, 11, 907. [Google Scholar] [CrossRef] [PubMed]
- Laurence, K.; Edward, R.L., Jr.; Shlomo, M.; Mark, E.M.; Mohammad, H.M.; Andrea, U.; John, A.H.W. Acromegaly: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2014, 99, 3933–3951. [Google Scholar] [CrossRef]
- Aydin, K.; Aydin, C.; Dagdelen, S.; Tezel, G.G.; Erbas, T. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly. Exp. Clin. Endocrinol. Diabetes 2016, 124, 198–202. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Wang, Y.; Zhang, X.; Jia, N.; Ma, Z.; Fu, J.; Liu, S. Papillary Thyroid Carcinoma in Patients with Acromegaly from a Single Center in China. World Neurosurg. 2021, 149, e22–e28. [Google Scholar] [CrossRef]
- dos Santos, M.C.; Nascimento, G.C.; Nascimento, A.G.; Carvalho, V.C.; Lopes, M.H.; Montenegro, R.; Montenegro, R., Jr.; Vilar, L.; Albano, M.F.; Alves, A.R.; et al. Thyroid cancer in patients with acromegaly: A case-control study. Pituitary 2013, 16, 109–114. [Google Scholar] [CrossRef]
- Dagdelen, S.; Cinar, N.; Erbas, T. Increased thyroid cancer risk in acromegaly. Pituitary 2014, 17, 299–306. [Google Scholar] [CrossRef]
- Kyeong, H.P.; Eun, J.L.; Gi, H.S.; Cheol, R.K. Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly. J. Clin. Endocrinol. Metab. 2020, 105, e1815–e1826. [Google Scholar]
- Bogazzi, F.; Russo, D.; Locci, M.T.; Chifenti, B.; Ultimieri, F.; Raggi, F.; Cosci, C.; Sardella, C.; Costa, A.; Gasperi, M.; et al. Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clin. Endocrinol. 2005, 63, 683–688. [Google Scholar] [CrossRef]
- Ochiai, Y.; Inoshita, N.; Iizuka, T.; Nishioka, H.; Yamada, S.; Kitagawa, M.; Hoteya, S. Clinicopathological features of colorectal polyps and risk of colorectal cancer in acromegaly. Eur. J. Endocrinol. 2020, 182, 313–318. [Google Scholar] [CrossRef] [PubMed]
- Freytag, D.; Günther, V.; Maass, N.; Alkatout, I. Uterine Fibroids and Infertility. Diagnostics 2021, 11, 1455. [Google Scholar] [CrossRef]
- Bachmann, G.A.; Bahouth, L.A.; Amalraj, P.; Mhamunkar, V.; Hoes, K.; Ananth, C.V. Uterine fibroids: Correlations of anemia and pain to fibroid location and uterine weight. J. Reprod. Med. 2011, 56, 463–466. [Google Scholar]
- Bruskewitz, R.C. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev. Urol. 2003, 5, 72–80. [Google Scholar] [PubMed]
- Lubitz, C.C.; Kong, C.Y.; McMahon, P.M.; Daniels, G.H.; Chen, Y.; Economopoulos, K.P.; Gazelle, G.S.; Weinstein, M.C. Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer 2014, 120, 1345–1352. [Google Scholar] [CrossRef] [PubMed]
- Aschebrook-Kilfoy, B.; Schechter, R.B.; Shih, Y.C.; Kaplan, E.L.; Chiu, B.C.; Angelos, P.; Grogan, R.H. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol. Biomark. Prev. 2013, 22, 1252–1259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kauffmann, R.M.; Hamner, J.B.; Ituarte, P.H.; Yim, J.H. Age greater than 60 years portends a worse prognosis in patients with papillary thyroid cancer: Should there be three age categories for staging? BMC Cancer 2018, 18, 316. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Women (n = 25) | Men (n = 9) | Total (n = 34) | p |
---|---|---|---|---|
BMI (kg/m2), mean ± SD | 29.68 ± 6.99 | 31.4 ± 3.28 | 30.1 ± 6.2 | 0.261 |
Age at diagnosis (years), mean ± SD | 45.0 ± 11.44 | 50.0 ± 5.41 | 43.0 ± 11.5 | 0.490 |
Age at the diagnosis of the first tumor (years), mean ± SD | 46.42 ± 10.27 | 48.6 ± 7.82 | 35.82 ± 21.88 | 0.482 |
Disease control, n (%) | C = 13 (52) | C = 4 (44.4) | C = 17 (50) | 0.305 |
PC = 5 (20) | PC = 4 (44.4) | PC = 9 (26.47) | ||
UC = 7 (28) | UC = 1 (11.2) | UC = 8 (23.52) | ||
DM, n (%) | 8 (32) | 0 (0) | 8 (23.5) | 0.075 |
Surgical therapy, n (%) | 20 (80) | 8 (88.9) | 28 (82.4) | 1 |
Gonadotropin deficiency, n (%) * | 9 (36) | 6 (66.7) | 15(44.1) | 0.1 |
Characteristic | Women (n = 25) | Men (n = 9) | Total (n = 34) | p |
---|---|---|---|---|
GH at diagnosis (ng/mL), mean ± SD | 17.85 ± 20.4 | 13.80 ± 9.61 | 17.65 ± 22.23 | 0.573 |
IGF-1 at diagnosis (ng/mL), mean ± SD | 625.2 ± 327.2 | 642.67 ± 151.57 | 629.8 ± 288.0 | 0.879 |
IGF-1 ULN, mean ± SD | 2.62 ± 1.3 | 2.76 ± 0.96 | 2.73 ± 1.26 | 0.942 |
Estimated diagnostic delay (years), mean ± SD | 9.32 ± 6.16 | 8.44 ± 5.61 | 10.35 ± 6.11 | 0.711 |
IGF-1 ULN × estimated diagnostic delay, mean ± SD | 19.35 ± 18.98 | 25.63 ± 19.96 | 21.0 ± 19.1 | 0.407 |
IGF-1 at diagnosis × estimated diagnostic delay, mean ± SD | 4282.1 ± 3801.2 | 5714.3 ± 3851.0 | 46,661.3 ± 3809.9 | 0.341 |
Localization | Benign (n) | Malignant (n) |
---|---|---|
Thyroid | 17 | 3 |
Uterus | 5 | 0 |
Prostate | 3 | 0 |
Colon | 4 | 1 |
Parathyroid | 2 | 0 |
Ovary | 1 | 0 |
Lungs | 1 | 0 |
Skin | 0 | 1 |
Pancreas | 1 | 0 |
Total | 34 | 5 |
Women | Benign (n) | Malignant (n) |
---|---|---|
Thyroid | 15 | 3 |
Uterus | 5 | 0 |
Large intestine | 3 | 1 |
Parathyroid | 2 | 0 |
Ovary | 1 | 0 |
Lungs | 1 | 0 |
Skin | 0 | 1 |
Pancreas | 1 | 0 |
Total | 27 | 5 |
Men | Benign (n) | Malignant (n) |
---|---|---|
Prostate | 3 | 0 |
Thyroid | 2 | 0 |
Colon | 1 | 0 |
Total | 6 | 0 |
Parameter | Patient with Tumors (n = 23) | Patients without Tumors (n = 11) | p |
---|---|---|---|
Men/Women, n | 4/19 | 5/6 | 0.045 |
BMI (kg/m2), mean ± SD | 30.06 ± 4.82 | 30.59 ± 8.72 | 0.837 |
Age at acromegaly diagnosis (years), mean ± SD | 45.0 ± 10.64 | 41.0 ± 12.78 | 0.308 |
Estimated diagnostic delay (years), mean ± SD | 8.65 ± 6.58 | 5.5 ± 3.8 | 0.155 |
Disease duration (years), mean ± SD | 8.65 ± 6.54 | 10.45 ± 4.08 | 0.412 |
GH at diagnosis (ng/mL), mean ± SD | 18.55 ± 20.92 | 22.56 ± 32.53 | 0.665 |
IGF-1 at diagnosis (ng/mL), mean ± SD | 666.6 ± 325.6 | 552.8 ± 180.6 | 0.200 |
IGF-1 ULN, mean ± SD | 2.92 ± 1.34 | 2.30 ± 0.95 | 0.185 |
IGF-1 ULN × estimated diagnostic delay, mean ± SD | 23.46 ± 19.52 | 14.60 ± 16.39 | 0.203 |
IGF-1 at diagnosis × estimated diagnostic delay, mean ± SD | 5158.8 ± 3804.3 | 3427.1 ± 3432.4 | 0.217 |
Disease control, n (%) | C =10 (43.5) | C = 7 (63.6) | 0.358 |
PC = 6 (26.1) | PC = 3 (27.3) | ||
UC = 7 (30.4) | UC = 1 (9.1) |
Parameter | Patient with Tumors (n = 23) | Patients without Tumors (n = 11) | p |
---|---|---|---|
Obesity, n (%) | 20 (87.0) | 6 (54.5) | 0.019 |
Diabetes mellitus, n, (%) | 8 (34.8) | 0 (0) | 0.037 |
Gonadotropin deficiency, n (%) * | 13 (56.5) | 5 (45.5) | 0.712 |
Sleep apnea, n (%) | Present 12 (52.2) Absent 11 (47.8) | Present 6 (54.5) Absent 5 (45.5) | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Plotuna, I.-S.; Balas, M.; Golu, I.; Amzar, D.; Vlad, A.; Moleriu, L.C.; Vlad, M. The Experience of a Single Tertiary Center Regarding Benign and Malignant Tumors in Acromegalic Patients. Medicina 2023, 59, 1148. https://doi.org/10.3390/medicina59061148
Plotuna I-S, Balas M, Golu I, Amzar D, Vlad A, Moleriu LC, Vlad M. The Experience of a Single Tertiary Center Regarding Benign and Malignant Tumors in Acromegalic Patients. Medicina. 2023; 59(6):1148. https://doi.org/10.3390/medicina59061148
Chicago/Turabian StylePlotuna, Iulia-Stefania, Melania Balas, Ioana Golu, Daniela Amzar, Adrian Vlad, Lavinia Cristina Moleriu, and Mihaela Vlad. 2023. "The Experience of a Single Tertiary Center Regarding Benign and Malignant Tumors in Acromegalic Patients" Medicina 59, no. 6: 1148. https://doi.org/10.3390/medicina59061148